KRAS and cancer: Compound 0375-0604 showed a strong anti-cancer activity by inhibiting the activation of KRAS proteins, and caused G2/M cell cycle arrest at the early stage and induced apoptosis at the later stage in H2122, H358 and H460 cell lines harboring KRAS oncogene.